Evandro de Azambuja, MD, PhD· @E_de_Azambuja · X·· 2 天前评分90
正文 · 原文
6-year results of Natalee (ribociclib): improvements in OS, BCSS, iDFS, DRFS - some subgroups analyses still required
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO @Annals_Oncology
413 浏览 · 13 赞 · 6 转发 · 1 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org帖内回复
- Cohen carine@carinecccc
@E_de_Azambuja @myESMO @Annals_Oncology We miss the OS curves in Europe, And the table of the deaths for other causes, which is driven by long term cardiovascular toxicities
来源：Evandro de Azambuja, MD, PhD · x.com